The MYC proto-oncogenes encode a family of transcription factors that are among the most
commonly activated oncoproteins in human neoplasias. Indeed, MYC aberrations or …

Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course
ranging from localized or spontaneously regressing to widely metastatic disease …

Chromatin is a macromolecular complex predominantly comprising DNA, histone proteins
and RNA. The methylation of chromatin components is highly conserved as it helps …

Loss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy
resistance. A genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved …

Neuroblastoma (NB), which is a subtype of neural-crest-derived malignancy, is the most
common extracranial solid tumor occurring in childhood. Despite extensive research, the …

Exciting therapeutic targets are emerging from CRISPR-based screens of high mutational-
burden adult cancers. A key question, however, is whether functional genomic approaches …

Efforts to therapeutically target EZH2 have generally focused on inhibition of its
methyltransferase activity, although it remains less clear whether this is the central …

Immunotherapy with anti-GD2 antibodies has advanced the treatment of children with high-
risk neuroblastoma, but nearly half of patients relapse, and little is known about mechanisms …

Despite great strides being achieved in improving cancer patients' outcomes through better
therapies and combinatorial treatment, several hurdles still remain due to therapy …

Notwithstanding cancer patients benefit from a plethora of therapeutic alternatives, drug
resistance remains a critical hurdle. Indeed, the high mortality rate is associated with …